NasdaqGS:BNTXBiotechs
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Weak Quarter And Lower 2026 Guidance
BioNTech's weak quarter and rising uncertainty
BioNTech (BNTX) reported first quarter sales of €118.1 million and a net loss of €531.9 million, alongside higher per share losses, following earlier pressure from tariffs concerns, leadership changes and lowered 2026 revenue guidance.
See our latest analysis for BioNTech.
At a share price of $99.35, BioNTech has seen a 1 month share price return of 8.96%, but the 1 year total shareholder return of 1.73% decline and 5 year total shareholder...